Healthcare Perspectives

Medical imaging is already an integral part of modern healthcare, but as hospitals face growing imaging demand and staffing challenges, new solutions using artificial intelligence have become an effective way to help ease the load.

On today’s episode of Siemens Healthcare Perspectives, you’ll hear a panel conversation discussing AI’s increasing role in radiology, recorded live at the Radiological Society of North America’s 2025 meeting. Held in Chicago, the conference is the world's largest scientific and educational meeting for the radiologic sciences.

For this discussion, host Katharina Schmidler is joined by Dr. John McMenamy, an Associate Professor of Radiology at the University of Colorado and Associate Radiology Chair at Denver Health; Kelly McFarland, WakeMed’s Executive Director of Imaging Services; and Dustin Allen, CT Scan Supervisor at WakeMed.

Together, these industry leaders explore what intelligent imaging looks like in action as well as its potential to enhance quality, accelerate diagnosis, reduce burnout, and improve overall patient care.

What you’ll learn in this episode:
How AI is transforming radiology by improving workflow efficiency
Automation allows more focus on patient care
Real-time feedback between technologists and radiologists enhances image quality
AI tools can help identify subtle findings that may be overlooked
Training programs are essential for developing the next generation of technologists
Collaboration between health systems can enhance the benefits of AI
The vital role technologists play in patient care

Connect with Katharina Schmidler
LinkedIn
Connect with John McMenamy
LinkedIn
Connect with Kelly McFarland
LinkedIn

Hosted on Acast. See acast.com/privacy for more information.

Access to quality healthcare is still out of reach for millions worldwide — particularly in low- and middle-income countries and underserved rural areas. One of the biggest drivers of this gap is a shortage of trained healthcare workers, a challenge made worse by workforce migration, limited local training opportunities, and uneven distribution of resources.

In this episode of Healthcare Perspectives, host Hagen Weissapfel, Director of Education and Customer Services for Global Access to Care at Siemens Healthineers, is joined by Melissa Culp, Executive Vice President of Member Engagement at the American Society of Radiologic Technologists (ASRT), and Dr. Geoff Ibbotson, surgeon and Executive Director of the Global Surgery Foundation (GSF). Together, they explore how education and training — scaled through digital innovation and local partnerships — can transform access to care for underserved communities.

From stories of practicing in isolation in remote Nepal, to advancing imaging education in Malawi, to building global learning platforms like SURGHub, Melissa and Geoff share how sustainable, in-country solutions can empower healthcare professionals, break down systemic barriers, and save lives.

What you’ll learn in this episode:
Why education is one of the most sustainable forms of impact in global health
How digital learning platforms like SURGHub are connecting providers in over 200 countries
The role of local leadership and trust in building effective training programs
How public awareness campaigns can inspire the next generation of medical imaging professionals
The life-or-death consequences of gaps in surgical technology access — and how training can close them
Why small, targeted investments can yield measurable improvements in health outcomes

Connect with Hagen Weissapfel
LinkedIn

Connect with Melissa Culp
LinkedIn

Connect with Geoff Ibbotson
LinkedIn
Hosted on Acast. See acast.com/privacy for more information.

Is it possible for artificial intelligence to make healthcare more environmentally sustainable?
In the field of radiology, AI may prove to be transformative. It has the potential to streamline processes, cut costs, and increase accuracy in imaging, diagnostics, and prevention.

When we talk about sustainability, we often think of carbon emissions or climate change. But environmental sustainability means something much broader in healthcare: it’s about how we can preserve resources, whether cost, energy, human capital, and reduce waste and pollution, all while improving health outcomes for everyone, everywhere.

Today, host Vibhas Deshpande, Head of Sustainability Innovation and Research, Americas at Siemens Healthineers, welcomes Dr. Kate Hanneman, cardiac radiologist at the University of Toronto; Dr. Charles Goh, Chief Medical Informatics Officer at Singapore General Hospital; and Tobias Heimann, head of the Department of Artificial Intelligence Germany at Siemens Healthineers, to explore how the rise of artificial intelligence is reshaping the conversation around sustainability in healthcare.
Together, they’re helping define what “responsible AI” really means—and what steps healthcare leaders can take now to ensure that AI benefits patients, clinicians and health systems and preserves global resources.

What you’ll learn in this episode:
Why eliminating data redundancy and using foundational models are keys to keeping AI development sustainable
AI is used to shorten imaging exams while still maintaining a high image quality, which contributes to energy savings
AI can help to arrive at correct diagnosis by improving clinical decision making and alignment to best practice to minimize waste in health systems
Sustainability is more than a metric of emissions or kilowatts—it’s also about how we invest intellectual and clinical capital, such as freeing clinicians to do what humans can do best: connect, interpret, and care.

Connect with Vibhas Deshpande
LinkedIn

Connect with Kate Hanneman
LinkedIn

Connect with Charles Goh
LinkedIn

Connect with Tobias Heimann
LinkedIn
Hosted on Acast. See acast.com/privacy for more information.

Metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, is a chronic liver condition that affects nearly 1 in 3 people worldwide. It is closely linked to obesity, type 2 diabetes, and metabolic syndrome. Unchecked, it can progress to a more severe form of disease called Metabolic Dysfunction-Associated Steatohepatitis (MASH).

Prognosticating the risk of disease progression in MASLD and MASH has traditionally involved liver biopsy, a process that involves removing a tissue sample with a hollow needle and then examining the sample under a microscope to diagnose and stage disease. However, biopsy has many limitations. Additionally, drug development for MASLD and MASH has proceeded slowly in part due to a reliance on liver biopsy to determine drug efficacy.

Recently, increasing evidence is suggesting that non-invasive options, for example, imaging examinations along with blood tests that assess likelihood of disease progression such as the Enhanced Liver Fibrosis (ELF) Test, may effectively reduce the need for the more invasive alternative. Key experts in MASLD and MASH share their perspectives about how clinical evidence supports a shift in the way patients with MASLD and MASH could be evaluated in clinical practice and in research.

Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Prof. William Rosenberg, Deputy Director of the Institute for Liver and Digestive Health at University College London as well as Dr. Veronica Miller, Director of the Forum for Collaborative Research at the University of California, Berkeley School of Public Health; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Associate Professor in the Section of Gastroenterology and Hepatology at Boston University.

What you’ll learn in this episode:
Liver biopsy creates several obstacles for patients and has limitations
Drug development faces challenges by the reliance on biopsy as a measure of treatment effectiveness
Non-invasive tools may be suitable alternatives to liver biopsy both in clinical practice and in drug development

Connect with Matt Gee
LinkedIn

Connect with Veronica Miller
LinkedIn

Connect with William Rosenberg
LinkedIn

Connect with Michelle Long
LinkedIn

Connect with Arun Sanyal
VCU.edu
Hosted on Acast. See acast.com/privacy for more information.

A reversible liver condition is the fastest growing cause of liver transplantation in Western countries: Metabolic dysfunction-associated steatotic liver disease—or MASLD—affects patients worldwide. It’s characterized by excessive fat accumulation in the liver and can progress into more severe forms of liver disease, potentially resulting in fibrosis, cirrhosis and liver failure.

Risk factors for developing liver disease include obesity, insulin resistance, type 2 diabetes, and metabolic syndrome. Genetics, unhealthy dietary habits, and a sedentary lifestyle can also play significant roles in its development. Diagnosis typically involves imaging examinations along with blood tests that assess liver function and rule out other causes of liver disease.

Disease management focuses on lifestyle modifications such as diet and exercise, though new medications are now being prescribed to slow and potentially reverse this condition. Regular monitoring of disease progression is also crucial for successful treatment.

In this episode, experts in the field of liver disease address the progress happening in the recognition, diagnosis and treatment of the disease.

Host Matt Gee, Director of Collaborations and External Engagement at Siemens Healthineers, is joined by Dr. Michelle Long, International Medical Vice President of Metabolic Dysfunction-Associated Steatohepatitis at Novo Nordisk and Director of Clinical Research for the Section of Gastroenterology and Hepatology at Boston University; Dr. Arun Sanyal, Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology at Virginia Commonwealth University; and Michael Betel, President and Founder of the Fatty Liver Alliance.

What you’ll learn in this episode:
One of the biggest obstacles to diagnosing MASLD before it progresses stems from the lack of visibility and awareness of the disease
MASLD is a reversible disease when caught in time
MASLD is more complex than a patient’s diet or lifestyle—metabolic dysfunction plays a role
Non-invasive testing has become an important tool in advancing patient care

Connect with Matt Gee
LinkedIn

Connect with Michelle Long
LinkedIn

Connect with Arun Sanyal
VCU.edu

Connect with Michael Betel
LinkedIn
Hosted on Acast. See acast.com/privacy for more information.